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Abstract
Background: Beta-blockers are commonly prescribed for patients with cardiovascular disease. Providers have been
wary of treating chronic obstructive pulmonary disease (COPD) patients with beta-blockers due to concern for
bronchospasm, but retrospective studies have shown that cardio-selective beta-blockers are safe in COPD and
possibly beneficial. However, these benefits may reflect symptom improvements due to the cardiac effects of the
medication. The purpose of this study is to evaluate associations between beta-blocker use and both exacerbation
rates and longitudinal measures of lung function in two well-characterized COPD cohorts.
Methods: We retrospectively analyzed 1219 participants with over 180 days of follow up from the STATCOPE
trial, which excluded most cardiac comorbidities, and from the placebo arm of the MACRO trial. Primary
endpoints were exacerbation rates per person-year and change in spirometry over time in association with
beta blocker use.
Results: Overall 13.9% (170/1219) of participants reported taking beta-blockers at enrollment. We found no statistically
significant differences in exacerbation rates with respect to beta-blocker use regardless of the prevalence of cardiac
comorbidities. In the MACRO cohort, patients taking beta-blockers had an exacerbation rate of 1.72/person-year versus
a rate of 1.71/person-year in patients not taking beta-blockers. In the STATCOPE cohort, patients taking beta-blockers
had an exacerbation rate of 1.14/person-year. Patients without beta-blockers had an exacerbation rate of 1.34/
person-year. We found no detrimental effect of beta blockers with respect to change in lung function over time.
Conclusion: We found no evidence that beta-blocker use was unsafe or associated with worse pulmonary outcomes
in study participants with moderate to severe COPD.
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Background
Chronic Obstructive Pulmonary Disease (COPD) is a
progressive and debilitating disease that burdens the
healthcare system with frequent office visits and
hospitalizations. In recent years, studies have exam-
ined both traditional treatments for COPD (long act-
ing beta agonists, long acting muscarinic antagonists,
and inhaled corticosteroids) [1, 2] as well as drugs
usually reserved for cardiovascular disease or infection
(statins and azithromycin) [3, 4] with respect to their
efficacy in reducing acute exacerbations of COPD
(AECOPD).
Beta-blockers are regularly prescribed in patients
with cardiovascular disease, a common comorbidity in
patients with COPD. Providers have historically been
reluctant to treat COPD patients with beta-blockers
due to a concern for precipitating bronchospasm.
These concerns have been expressed in review articles
and practice guidelines that cited case studies of acute
bronchospasm in patients treated with non-selective
beta blockers [5, 6]. Cardioselective beta-blockers (or
beta-1-blockers) have a 20 fold greater affinity for β-1
receptors and less theoretical risk for bronchocon-
striction. Within the last decade, studies have
highlighted concern for the use of beta-blockers in
patients with COPD [6, 7]; however, Cochrane Re-
views in 2005 and 2010 concluded that cardioselective
beta blocker use in patients with COPD had no
significant adverse effects on FEV1, respiratory
symptoms, or responsiveness to beta-agonist inhaled
therapy. Sub-group analysis extended this to patients with
severe obstruction as well as those with bronchodilator
reversibility demonstrated on spirometry [8].
Multiple retrospective studies have suggested that beta-
blockers may reduce the mortality of patients with COPD
as well as the risk of AECOPD [9, 10]. Mortality as an
endpoint in studies linking COPD and beta-blockers is
confounded by difficulty determining whether the benefit
of the drug is related to its effects on the lung or on
coexistent cardiovascular disease [11, 12]. Examining the
relationship between beta-blocker use, serial spirometry
and rates of AECOPD may provide a more useful depic-
tion of the effect of these medications on lung disease.
The COPD Clinical Research Network has conducted
several randomized, placebo-controlled prospective trials
in study participants with COPD assessing rates of
AECOPD.
The STATCOPE study showed no benefit attributable
to daily simvastatin, whereas the
MACRO trial demonstrated reduced rates of AECOPD
with azithromycin treatment [3, 4]. The STATCOPE
cohort and the placebo arm of MACRO provide a
unique opportunity to analyze the effect of beta-blockers
on AECOPD in a group of COPD patients with a fairly
high prevalence of cardiovascular comorbidities (MACRO)
as compared with a group in which cardiovascular comor-
bidities were mostly excluded (STATCOPE). Given that
beta-blockers are likely to have a greater impact on patients
with cardiovascular disease, we hypothesized that beta-
blockers would associate with lower rates of COPD exacer-
bation in the MACRO cohort when compared to the
STATCOPE cohort due to a higher burden of underlying
cardiovascular comorbidity. That is to say, a population
with a higher prevalence of cardiac comorbidities may have
a greater symptomatic benefit from treatment with beta-
blockers when compared with a population with little or no
cardiac comorbid disease.
Methods
Patient population
We performed a retrospective review of 1219 study par-
ticipants who had at least 180 days of follow up from
the STATCOPE trial or the placebo arm of the MACRO
trial. Entry criteria for the MACRO trial included having
a ratio of forced expiratory volume in one second to
forced vital capacity (FEV1/FVC) < 70% and being at
high risk for experiencing an AECOPD as a result of
using supplemental oxygen, or being treated with oral
glucocorticoids, antibiotics or being hospitalized in the
previous year for an AECOPD. Patients also had no
exacerbation within 4 weeks of enrollment 4. Patients in
the azithromycin treatment arm of the MACRO study
were excluded due to the significant treatment effect of
azithromycin on reducing exacerbation rate. The STAT-
COPE trial had similar inclusion criteria, but excluded
patients who were taking a statin, had contraindication
to the use of statins or who were found to have an indi-
cation for statin therapy [3]. In both the MACRO and
STATCOPE studies exacerbations were defined as “a
complex of respiratory symptoms (increased or new
onset) of more than one of the following: cough,
sputum, wheezing, dyspnea, or chest tightness with a
duration of at least 3 days requiring treatment with anti-
biotics or systemic steroids.”
Spirometry
Spirometry was obtained at enrollment and at completion
of the study. Each cohort’s spirometric data were analyzed
for significant changes over time. The MACRO cohort
had spirometry performed at enrollment then at either 6
or 12 months. The STATCOPE cohort had spirometry at
enrollment then at 12 or 24 months.
Statistics
The primary study endpoint was rate of acute exacerba-
tion of COPD in each of the four study groups; MACRO
on beta-blocker, MACRO off beta-blocker, STATCOPE
on beta-blocker and STATCOPE off beta-blocker. COPD
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exacerbation rates were compared with the use of an
event rate ratio; i.e., the number of exacerbations per
patient year. Additionally, changes in spirometric data
were analyzed over time for each of the four study
groups. P-values for mean rate of decline were computed
by t-test. Exacerbation rates were compared among the
groups using SAS data analysis software.
Results
Of the 1219 participants included in our study, 170
(13.9%) reported taking beta-blockers at enrollment. In
the STATCOPE cohort 63 of 688 (9.2%) participants
were taking beta-blockers along with 107 of 531 (20.2%)
in the MACRO placebo arm. The majority of partici-
pants in the study had severe or very severe airflow
obstruction classified as GOLD stage III or IV. Those
taking beta-blockers tended to have a slightly higher
FEV1, however we found no statistically significant dif-
ference between the groups with respect to demographic
characteristics, smoking history or spirometric data
(Table 1). As expected, the patients in STATCOPE had a
significantly decreased rate of cardiac comorbidities as
compared with the MACRO cohort (Table 2). Given the
disparity in cardiac comorbidities, the vast majority of
patients on beta-blockers in the STATCOPE cohort
appeared to be taking the medication for hypertension
rather than coronary artery disease (CAD) or a history
of myocardial infarction (MI); whereas, a significant
percentage in the MACRO cohort was taking the
medication for CAD or MI (Table 2).
Patients in the STATCOPE cohort taking beta-
blockers had the lowest rate of AECOPD (1.14/per-
son-year, 95% CI = 0.81–1.46), followed by patients in
STATCOPE not taking beta-blockers (1.34/person-
year, 95% CI = 1.22–1.46). In the MACRO cohort the
rate of AECOPD was higher when compared with
STATCOPE, but nearly identical with respect to beta-
blocker usage within the cohort (Table 3). We found
no statistically significant difference between patients
taking beta-blockers and the corresponding cohort off
beta-blockers.
Table 1 Demographics, smoking history and spirometry. No statistically significant difference between study groups in within each
trial
Macro -BB Macro + BB Statcope -BB Statcope + BB
N 469 110 625 63
Age - years (SD) 64.6 (8.6) 67.3 (8.0) 62 (8.51) 63.4 (7.9)
Men - N (%) 273 (58.2%) 75 (67.6%) 349 (55.8%) 35 (55.6%)
Race
% Black 16.8 11.7 20.3 25.4
% White 79.5 82.9 77.1 73
Smoking History
Pack years - mean (SD) 59.7 (33.7) 59.4 (28.5) 50.0 (26.3)* 49.1 (28.9)
Current Smoker - % 22.4 21.6 30.6* 34.9
Spirometry - %
GOLD 2 21.8 44.1 34.3 38.1
GOLD 3 42.4 36 33.9 34.9
GOLD 4 35.8 19.8 31.8 27
FEV1 - Liters (SD) 1.09 (0.51) 1.31 (0.52) 1.20 (0.57)* 1.30 (0.62)
FEV1 - mean % predicted value 38.3 46.8 41.8* 45.8
FVC - Liters (SD) 2.61 (0.89) 2.81 (0.79) 2.68 (0.92) 2.65 (0.95)
FVC - % predicted value 69.4 74.6 70.7 70.3
FEV1/FVC 41.8 46.8 44.6 48.8
Chronic Bronchitis - % 44.8 50.5 48.9 52.5
* - p < 0.05 when compared with corresponding subgroup MACRO cohort
Table 2 Percent of patients self-reporting comorbid conditions
by study group
Macro -BB Macro + BB Statcope -BB Statcope + BB
N 424 107 625 63
Hypertension 193 (46%) 88 (82%) 180 (29%)* 53 (84%)
Diabetes 49 (12%) 25 (23%) 21 (3%)* 3 (5%)*
CAD 54 (13%) 53 (50%) 12 (2%)* 2 (3%)*
MI 40 (9%) 38 (36%) 5 (1%)* 3 (5%)*
* - p < 0.05 when compared with corresponding subgroup MACRO cohort
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Percent of subjects free of exacerbation over time is
depicted in Fig. 1. In both the MACRO and STATCOPE
cohorts, the patients taking beta-blockers had a higher
percentage of patients free of exacerbation though this
difference did not reach statistical significance in either
group. Of note, there was no patient dropout during this
period as all patients had at least 180 days of follow up.
Additionally, we studied the change in spirometric
data over time for all patients (1063/1219, 87.2%) who
had follow-up spirometry. The data shows that the
presence of beta-blocker medications had no clinically
or statistically significant effect on the change in airflow
limitation in this cohort.
Discussion
We found no harmful effect of beta-blockers with
respect to change in FEV1 over time and no statistically
significant difference in the rate of acute exacerbation of
COPD in an at-risk population, regardless of the
presence of cardiac comorbidity.
Other retrospective studies have shown beta-blockers
to be beneficial in patients with COPD but those obser-
vations may represent cardiovascular benefits of beta-
blockers rather than pulmonary specific improvements
in COPD symptoms or severity.
One recent Swedish nationwide observational study
concluded that patients with COPD discharged on a
beta-blocker after an MI had a lower all-cause mortality
compared with those not discharged on a beta-blocker
[13]. However, a large retrospective study showed that
patients with severe COPD or asthma had no mortality
benefit from taking beta-blockers after MI [14]. Morta-
lity has been shown to be improved in COPD patients
specifically taking beta-blockers as monotherapy for
hypertension [15]. The reduced prevalence of cardiac
comorbidity in the STATCOPE cohort provided an
opportunity to compare the effectiveness of beta-
blockers in a COPD population with (MACRO) and
without (STATCOPE) self-reported cardiac disease. We
found no significant difference in rates of AECOPD with
respect to beta-blocker use in the cohort with increased
cardiac comorbidities. However, there was a slightly
lower rate of AECOPD in the patients taking beta-
blockers in the STATCOPE cohort and the percent free
of exacerbation at 90 and 180 days was higher in pa-
tients taking beta-blockers in each cohort. Our inability
to detect a statistically significant difference between
patients with versus without cardiac disease may be a
result of the relatively low number of patients who were
taking beta-blockers and reported cardiac comorbidi-
ties. Importantly, we did find that COPD patients
taking beta-blocker medications did no worse with re-
spect to exacerbation or change in spirometry over a
relatively long follow up period when compared with
patients who were not taking beta-blockers (Table 4).
In accordance with prior studies [13–16], this finding
provides further proof that beta-blockers are safe to
use in COPD patients.
Proposed mechanisms by which beta-blockers may
have an effect on the COPD process and potentially
decrease exacerbation frequency include reduction of
ischemic burden and tempering the sympathetic nervous
system. COPD has been associated with systemic
Table 3 AECOPD per person year by study group
Statcope N Exacerbation rate per person-year
(95% CI)
+BB 63 1.14 (0.81,1.46)
−BB 625 1.34 (1.22,1.46)
Macro
+BB 107 1.72 (1.37,2.08)
−BB 424 1.71 (1.53,1.88)
A
B
Fig. 1 Panel (a) - Percent free of exacerbation by beta-blocker use in
the Macro placebo arm at 0, 30, 60, 90 and 180 days. Panel (b) –
Percent free of exacerbation by beta-blocker use in the
STATCOPE trial
Duffy et al. Respiratory Research  (2017) 18:124 Page 4 of 7
inflammation, and it has been proposed that the negative
effects of neurohumoral activation (such as inflamma-
tion, cachexia) can contribute to the cycle of COPD ex-
acerbation and pathophysiology. Beta blockade
theoretically could have an impact on neuro-humoral ac-
tivation and COPD. [17] In addition, animal models have
shown that beta-blockers given chronically can increase
the density of beta-receptors and reduce airway respon-
siveness in mice with asthma [18]. Those on beta-
blockers may have had more effective blood pressure
control and a reduction in complications of less opti-
mally treated diastolic dysfunction which has been
linked to the development of acute exacerbations [19].
Other observational studies have shown conflicting re-
sults. For instance, Bhatt and colleagues evaluated a co-
hort of over 3000 patients from the COPDGene cohort
and found that patients taking beta-blockers had a de-
creased incidence on AECOPD. This association held
true for severe exacerbations as well as mild to moderate
exacerbations [20]. Short et.al. performed a retrospective
review of COPD patients on and off beta-blockers and
showed that patients taking beta-blockers had lower
rates of AECOPD and mortality regardless of the inhaled
pulmonary medication regimen in each group [21].
However, in both of these trials, patients had less
severe airflow obstruction in comparison to our popu-
lation (Table 5). Our inability to find a significant ef-
fect of beta-blockers may be secondary to the severity
of COPD in this cohort. These patients were enrolled
due to an increased risk for COPD exacerbation and
had relatively severe obstruction on spirometry. This
high burden of respiratory disease may overshadow
the relatively lesser burden of cardiovascular disease
in this population. We also found a high prevalence
of chronic bronchitis in each cohort, which was not
reported in the other studies, but may have influ-
enced the rate of exacerbation and limited the efficacy
of beta-blocker therapy.
Additionally, the expected outcome of beta-blockers
having a greater effect on the cohort with cardiac
Table 4 Change in spirometry over time with respect to beta-blocker use
Statcope ΔFEV1 in mL (SD) Δ %FEV1 (SD) Δ FVC in mL (SD) Δ %FVC (SD)
+BB (N = 54) −13.1 (268.8) 0.33 (9.7) −21.7 (382.9) 0.59 (10.2)
−BB (N = 531) −53.9 (241.3) −1.24 (8.96) −88.8 (444.4) −1.43 (12)
P- value 0.29 0.25 0.23 0.18
Macro
+ BB (N = 96) −13.9 (233.9) −0.55 (8.61) n/a −0.52 (12.3)
−BB (N = 381) −12.7 (196) −0.31 (6.5) n/a −0.47 (12.4)
P- value 0.96 0.76 0.97
n/a not included as data reported for only 4 participants
Table 5 Demographic comparison of retrospective studies on beta-blocker use in COPD
Study Bhatt
et al. [20]
Rutten
et al. [11]
Short
et al. [21]
Van Gestel
et al. [16]
Current Study
MACRO4 STATCOPE3
N (on Beta blockers) 474 665 796 462 110 63
Age 66.8 64.7 69.8 69 67.3 63.4
% Men 60.1% 49.8% 42.7% 82.0% 67.6% 55.6%
Mean Pack years 56.8 n/a 44.3 n/a 59.4 49.1
% Current Smoker n/a 34.6% n/a 35.0% 21.6% 34.9%
FEV1 (L) 1.5 n/a n/a n/a 1.31 1.3
FEV1 mean % predicted 53.2% n/a 65% n/a 46.8% 45.8%
% GOLD 3/4 38.4% n/a n/a n/a 55.8% 61.9%
%Chronic bronchitis n/a n/a n/a n/a 50.5% 52.5%
% CAD or revasc 44.7% 38.3% (IHD) 70% (CV dz) 25% 50% 3%
% Diabetes 24.1% 24.1% 21% 17% 23% 5%
% Hypertension 84.4% 66.8% n/a 49% 82% 84%
% History of MI n/a 9.6% n/a 33% 38% 5%
n/a data not available
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comorbidity (MACRO) may not have been present due
to baseline differences in the two groups. The MACRO
cohort on beta-blockers trended to be an older popula-
tion, with an increased number of pack-years which may
be reflective of a sicker patient population when com-
pared with the STATCOPE cohort on beta-blockers
(Table 1).
Study limitations
The relatively low number of patients taking beta-blockers
at enrollment in these studies limited our ability to show a
statistically significant difference between the groups with
respect to demographic and baseline spirometry (Table 1).
Medications and comorbidities were self-reported by the
patients at enrollment. Information regarding dosage and
specific type of beta-blocker (i.e. beta-1 selective or nonse-
lective) medication was not available. Though there is in-
herent weakness in the design of all retrospective analyses,
the data presented are derived from well-constructed,
prospective, large multicenter trials. Despite the limita-
tions, our study is the first to compare the efficacy of
beta-blockers in a COPD population with higher versus
lower prevalence of cardiac comorbidities.
Conclusion
We found no evidence that beta-blockers significantly
affected the rate of AECOPD regardless of whether the
patients did or did not report cardiac comorbidities. We
did find that beta-blockers had no detrimental effect on
lung function in a population that was at increased risk
for AECOPD. Because previous observational studies
have reported conflicting data, the question will require
a large, prospective and randomized trial to determine
the benefits of beta-blocker therapy in COPD patients.
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